All In Biotech

Investigational drug · Phase 3

MB12

Also called: Proposed Pembrolizumab Biosimilar

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non Squamous Non Small Cell Lung Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "MB12"

First trial start

2024

Dec 30, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MB12", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non Squamous Non Small Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "MB12" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 43 on PubMed

Also in development for Non Squamous Non Small Cell Lung Cancer

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • EU-sourced KeytrudaPhase 32 trials

    Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer

  • US-sourced KeytrudaPhase 32 trials

    Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer

  • and CarboplatinPhase 21 trial

    CrystalGenomics, Inc. · Non Squamous Non Small Cell Lung Cancer

  • IDP-001Phase 21 trial

    InduPro, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.